Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase I/II Study to Assess the Safety and Clinical Activity of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients

Trial Profile

An Open-label, Phase I/II Study to Assess the Safety and Clinical Activity of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYAD 01 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Acronyms DEPLETHINK
  • Sponsors Celyad
  • Most Recent Events

    • 06 Nov 2019 Interim results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
    • 04 Sep 2019 According to a Celyad media release, first patient enrolled in cohort 3 (300 million cells) has been dosed with CYAD-01 produced with the OptimAb manufacturing process. Preliminary data from patients enrolled treated with CYAD-01 produced with the OptimAb process anticipated by the end of 2019.
    • 01 Jul 2019 According to a Celyad media release, initial clinical data from cohort 4 using the OptimAb manufacturing process are expected by year-end 2019 and full results are anticipated in first quarter 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top